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ABBREVIATIONS 
 
aHR, adjusted hazard ratio 
AIDS, acquired immunodeficiency syndrome 
ART, antiretroviral therapy 
CFAR, Centers for AIDS Research 
CI, confidence interval 
CNICS, CFAR Network of Integrated Clinical Systems 
CVD, cardiovascular disease 
FIB-4, Fibrosis-4 score 
HCV, hepatitis C virus 
HIV, human immunodeficiency virus 
LDL, high density lipoprotein 
MI, myocardial infarction 
PLWH, people living with HIV 
RNA, ribonucleic acid 
T1MI, Type 1 myocardial infarction 
T2MI, Type 2 myocardial infarction 
 
 
 
 
Keywords: hepatitis C virus (HCV), human immunodeficiency virus (HIV), myocardial 
infarction, Type 2 myocardial infarction, people living with HIV (PLWH)  
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ABSTRACT 
Word count: 195 words 
 
Hepatitis C virus (HCV) is common among people living with HIV (PLWH). The potential 
for extrahepatic manifestations of HCV, including myocardial infarction (MI), is a topic of 
active research. MI is classified into types, predominantly atheroembolic Type 1 MI (T1MI) 
and supply-demand mismatch Type 2 MI (T2MI). We examined the association between 
HCV and MI in the CFAR Network of Integrated Clinical Systems (CNICS), a multi-center 
clinical cohort of PLWH. MIs were centrally adjudicated and categorized by type using the 
Universal MI definition. We estimated the association between chronic HCV (RNA+) and 
time to MI adjusting for demographic characteristics, cardiovascular risk factors, clinical 
characteristics and substance use. Among 24,755 PLWH aged ≥18, there were 336 T1MI 
and 330 T2MI during a median of 4.2 years of follow-up. HCV was associated with a 68% 
greater risk of T2MI (adjusted hazard ratio (aHR) 1.68, 95% CI: 1.22, 2.30) but not T1MI 
(aHR 0.96, 95% CI: 0.63, 1.45). In a cause-specific analysis of T2MI, HCV was associated 
with a 2-fold greater risk of T2MI attributed to sepsis (aHR 2.26, 95% CI: 1.34, 3.81). 
Extrahepatic manifestations of HCV in this high-risk population are an important area for 
continued research. 
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Word count: 2736 words 
 
Survival of people living with human immunodeficiency virus (HIV) (PLWH) has 
improved dramatically in the last 20 years, owing to a decline in mortality associated with 
antiretroviral therapy (1-5). During the same period, morbidity and mortality from non-
AIDS-defining illnesses, including cardiovascular disease (CVD), have increased in this 
group (6-9). PLWH are at higher risk of myocardial infarction (MI) compared to the general 
population (10). Recent work has shown that among PLWH approximately half of incident 
MIs are Type 2 MI (T2MI) (11), whereas in the general population T2MI accounts for a 
much smaller proportion of MIs (12-20). In contrast to classical atheroembolic Type 1 MI 
(T1MI), T2MI results from myocardial oxygen demand-supply mismatch, a scenario that 
may result from a variety of conditions, including sepsis, illegal stimulant or drug-induced 
vasospasm, decompensated heart failure, and hypotension (21).  
A large body of literature has linked CVD to chronic infection with hepatitis C virus 
(HCV), a common viral infection impacting an estimated 10 to 30% (22-26) of PLWH in the 
United States (US). Observational evidence supports an association between HCV and 
clinically evident CVD, in both the general population (27, 28) and in PLWH (29). Yet 
studies in the general population focusing on the role of HCV in coronary artery disease risk 
are inconclusive (27) and, when restricting to MI only, have generally not supported an 
association (30-33). One recent study found a higher risk of MI in those with HCV but only 
among the subgroup with high levels of total and low density lipoprotein (LDL) cholesterol 
(34).  Among PLWH, very little research has assessed the association of HCV-coinfection 
with MI and, to our knowledge, none has examined whether such an association may differ 
by MI type.  
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Due to the higher prevalence of MI and HCV infection among PLWH, unclear 
associations between HCV and MI in the general population, different patterns of MI types 
among PLWH, and an increasing availability of highly effective treatments for HCV, it is 
important to establish whether HCV increases the risk of MI for PLWH. In this study, we 
sought to estimate the relative risk of incident T1MI and T2MI among PLWH who are 
coinfected with HCV compared to those who are not. 
 
METHODS 
Study population 
The Centers for AIDS Research (CFAR) Network of Integrated Clinical Systems (CNICS) 
cohort is a population of >32,000 PLWH who have received HIV care at one of 8 sites in 
the US from 1995 to the present and have consented to participation in CNICS research 
activities (35). Included in this study were all participants ≥18 years of age from six CNICS 
sites with comprehensive access to inpatient and outpatient electronic medical records 
(Johns Hopkins University; University of Alabama at Birmingham; University of California, 
San Diego; University of California, San Francisco; University of North Carolina at Chapel 
Hill; and University of Washington, Seattle). This analysis includes participants who 
contributed person-time during the years 1998 through 2016; the majority of follow-up 
occurred from 2010 to 2016. Entry into the study cohort was defined as six months after 
CNICS cohort entry or the first date of surveillance for MI events at the study site – 
whichever was later. Participants were followed until nine months after the date of last clinic 
visit or laboratory result (36), death, or the administrative censoring date for the site. 
Institutional review boards at each institution have approved CNICS research activities. 
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CNICS data repository 
Each CNICS site captures demographic, clinical, medication and laboratory data from all 
outpatient and inpatient encounters, including cardiac biomarkers, medications, diagnoses, 
and historical clinical information. In addition, participants were invited to complete an 
assessment of patient reported outcomes (PRO) and measures at 4-6 month intervals, 
capturing use of tobacco, alcohol and illicit substances as well as other health behaviors (37). 
 
Variables of interest 
Ascertainment and adjudication of MI events in this cohort has been described in detail 
elsewhere (38). Briefly, identification of potential events was done centrally using multiple 
criteria, including MI-associated diagnostic codes (International Classification of Diseases, 
Ninth Revision, 410.00, 410.01, and 410.10), having an invasive cardiac procedure 
(percutaneous coronary intervention or bypass grafting), and elevated cardiac biomarkers. 
Sites then generated clinical data packets including primary data for all potential MI events. 
Packets contained chart notes, electrocardiograms, imaging and procedure reports, and 
laboratory values, but antiretroviral medication data were redacted. Packets were reviewed 
centrally by two physician experts to adjudicate MIs as definite or probable and to classify 
them as T1MI or T2MI, based on the Universal MI definition (11, 21, 38). While the 
Universal MI definition includes other types (e.g., cardiac procedure-related type 4 MI), these 
were uncommon (<10 cases) and so are not further discussed. In cases of discrepant 
findings, the assessment of a third reviewer was used to break ties (38).  
Laboratory test results obtained in the course of routine care were used to determine 
HCV status. Chronic HCV infection was defined as a detectable result (i.e., above the lower 
limit of detection) for the most recent HCV ribonucleic acid (RNA) test before entry into 
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the study cohort, and all remaining participants in the study cohort were classified as not 
chronically infected with HCV. 
 
Covariates 
Covariates were taken from measurements available at study entry, except for height 
used to calculate body mass index which could be measured at any time. Diabetes was 
defined as any one of the following: hemoglobin A1c ≥ 6.5%, a clinical diagnosis of diabetes 
mellitus type 1 (T1DM) or type 2 (T2DM) and prescription of diabetes-related medication, 
or prescriptions of a diabetes-specific medication. Treated hypertension was defined as a 
clinical diagnosis of hypertension and documentation of an antihypertensive medication. 
Hepatitis B virus infection was defined on the basis of a positive result for hepatitis B e-
antigen or surface antigen or deoxyribonucleic acid (DNA). Fibrosis-4 (FIB-4) index, a 
noninvasive measure of predicted liver fibrosis, was calculated as: [age (years) × aspartate 
aminotransferase (AST)]/[platelet count × alanine aminotransferase (ALT)
1/2
] (39) and 
categorized as >3.25 (severe fibrosis), 1.45-3.25 (indeterminate), <1.45 (no severe fibrosis).  
History of injecting drug use was derived from HIV transmission risk factor reported 
at CNICS cohort entry and was coded as 1 if the participant reported membership in a 
transmission risk group that included injecting drug use. Ever-smoker was the presence of a 
tobacco-use diagnosis or self-report of tobacco use. Use of methamphetamine, 
cocaine/crack, marijuana, opiates (illicit use), cigarettes and alcohol at study cohort entry 
were available for a subset of participants (approximately 13%) as assessed by the ASSIST 
questionnaire (40). Drug and cigarette use categories were current, former or never use. 
Alcohol use was the AUDIT-C score derived from a short screening questionnaire about the 
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frequency and quantity of alcohol consumed (41). Values range from 0 (least alcohol use) to 
12 (most alcohol use). 
 
Statistical analysis 
Approximately 87% of participants were missing information about 
methamphetamine, cocaine, opiate, marijuana, cigarette and alcohol use (from PROs) at the 
start follow-up. Missing values in all analytic variables were multiply imputed using chained 
equations with fully conditional specification in the R package mice (42) based on all other 
covariates yielding 100 complete datasets. For each complete dataset, the association 
between chronic HCV infection and time to the patient’s first MI event for each complete 
dataset was estimated using Cox proportional hazard regression models. Resulting inferences 
were pooled using Rubin’s Rules (43). Separate models examined T1MI, T2MI, cause-
specific T2MI outcomes, and a composite outcome of all MIs. Models were adjusted for 
potential confounding factors. Minimally adjusted models considered only age and sex, while 
fully adjusted models included study site, demographic characteristics (age, sex, 
race/ethnicity, men who have sex with men), clinical characteristics (diabetes, treated 
hypertension, statin use, body mass index, lipid profile, lowest CD4+ cell count, hepatitis B 
virus infection, HIV viral load, antiretroviral therapy), history of injecting drug use, ever 
smoker and self-reported substance use (smoking, alcohol use, illicit substance use). 
Proportionality of hazards was assessed using Schoenfeld residuals for a random subset of 
imputations, and no consistent deviations were discovered. Statistical analyses were 
conducted in R version 3.4.3 (2017-11-30). 
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Sensitivity analysis 
Analyses were repeated to estimate the risk of MI outcomes associated with prior 
HCV infection in the absence of chronic infection at the time follow-up began. The exposed 
group for that analysis was those with a positive finding on the most recent HCV antibody 
test coupled with a negative finding for the most recent RNA test prior to baseline.  
Because liver fibrosis was considered to be a potential mediator of the relationship 
between HCV and MI, it was not included in the regression models for the main analyses. 
However, in an effort to informally explore the extent to which liver fibrosis may serve as a 
mechanistic link between HCV and MI, the main analyses for T1MI, T2MI and all MIs were 
repeated with the stratum predicted to have severe fibrosis (FIB-4 > 3.25) and the stratum 
predicted to have no severe fibrosis (FIB-4 <1.45).  
 
 
RESULTS 
Among 23,407 PLWH, we observed 336 T1MI and 330 T2MI (666 MI total) during 
a median of 4.7 years of follow-up. In all, 2,280 (9.2%) had evidence of chronic HCV 
infection at the beginning of MI follow-up. The median age of participants was 40, 81% 
were male, and approximately half were non-white (Table 1). Compared with participants 
without HCV infection, those with HCV tended to be older and were less likely to report 
being men who have sex with men. Unsurprisingly, a much larger proportion (61.5% vs. 
15.0%) had a history of injecting drug use (Table 1). The crude incidence rate for all MI 
events was 5.0 (95% CI: 4.7, 5.2) per 1000 person-years, and the rate was 4.6 (95% CI: 4.4, 
4.9) among participants without chronic HCV and 8.2 (95% CI: 7.1, 9.4) among those with 
chronic HCV per 1000 person-years. T2MI events were attributed to a variety of causes 
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(Table 2), with sepsis/bacteremia and stimulant-induced vasospasm being the most 
common. 
Using a composite MI outcome, chronic HCV infection was associated with a 36% 
greater risk of MI after adjusting for demographic characteristics, traditional cardiovascular 
disease risk factors, clinical characteristics and substance use (adjusted hazard ratio (aHR) 
1.36, 95% confidence interval (CI):1.06, 1.73) (Figure 1). Considering each MI type, chronic 
HCV infection was associated with a 68% higher risk of T2MI (aHR 1.68, 95% CI: 1.22, 
2.30) after adjusting for potential confounders, but HCV was not associated with T1MI 
(aHR 0.96, 95% CI: 0.63, 1.45). In further analyses examining adjudicated causes of T2MI, 
HCV was found to be associated with an approximately 2-fold greater risk of T2MI 
attributed to sepsis (aHR 2.26, 95% CI: 1.34, 3.81) but was not associated with T2MI 
attributed to use of a stimulant (aHR 0.96, 95% CI: 0.15, 6.14) or other causes (aHR 1.47, 
95% CI: 0.92, 2.34) after covariate adjustment (Figure 1). Because there were a small number 
of T2MI events attributed to use of a stimulant, we assessed the stability of the model for 
this outcome by estimating a model adjusted for age, sex, and history of injecting drug use – 
which gave relatively consistent results (Supplementary Table 1). 
In sensitivity analysis, we investigated whether the risk of MI outcomes associated 
with chronic HCV appears to differ based on extent of liver fibrosis. In the stratum without 
predicted fibrosis (FIB-4 < 1.45), although HCV was associated with a 58% higher risk of 
T2MI after accounting for potential confounders (aHR 1.58, 95% CI: 0.95, 2.64), this 
relation was not statistically significant (Figure 2). In a separate analysis, we found that there 
was no association between prior HCV infection without chronic HCV infection (antibody-
positive, RNA-negative) and any MI outcome (Supplementary Figure 1). 
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DISCUSSION 
In this cohort of PLWH across the US, we found that HCV/HIV-coinfected 
persons experienced a greater risk of T2MI and this was particularly driven by the relation 
between chronic HCV infection and T2MI attributed to sepsis. In contrast, there was no 
significant increase in the risk of having T1MI among coinfected persons. To our 
knowledge, this is the first study to assess the association between HCV infection and MI 
types, particularly T2MI, among PLWH.  
In general, it is our findings with respect to T1MI that are likely to be most 
comparable to prior studies of this question, which in the general population have not found 
an association between chronic HCV infection and MI (30-33). Two prior studies in PLWH 
were inconclusive. Bedimo et al. (44) reported a 25% higher risk of acute MI in U.S. veterans 
infected with HCV and HIV compared to those infected with HIV alone, however this 
association did not reach the level of statistical significance, while the D:A:D study group 
found no association between HCV seropositivity and MI (45). Although both of these 
studies ascertained composite MIs without reference to type, both defined MIs using 
administrative diagnosis codes. The proportion of MIs detected in prior studies that were 
T1MI versus T2MI is not known, however the ability of administrative codes to detect 
T2MI seems generally poor (46). Therefore, prior evidence appears to concur with our 
finding that chronic HCV is not associated with classical, atheroembolic T1MI. 
We observed a greater risk of T2MI associated with HCV and, more specifically, an 
approximately 2-fold greater risk of T2MI due to sepsis in those coinfected with HCV and 
HIV compared to those infected with HIV alone. This may be related to consequences of 
HCV infection, such as liver dysfunction and/or chronic inflammation, or differences in 
sepsis risk factors between HCV-infected and uninfected participants. While our results 
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suggest a higher risk of T2MI attributed to sepsis in those with evidence of chronic HCV 
infection, we did not detect a similar relation when considering prior HCV infection without 
evidence of viremia. This lends credence to the hypothesis that ongoing chronic infection or 
associated biological factors (in addition to risk behaviors associated with HCV exposure) 
may play a role in the risk of T2MI resulting from sepsis or of sepsis, itself. A large study of 
hemodialysis patients in the US, which found that the risk of bacteremia was greater in those 
with HCV infection, provides support for HCV as a risk factor for sepsis (47), and the 
landmark REVEAL study found that HCV seropositivity is associated with an 50% higher 
risk of mortality due to circulatory diseases (48). 
In sensitivity analysis, stratification by predicted liver fibrosis score (FIB-4) suggested 
potential heterogeneity in the association of HCV with T2MI by extent of liver fibrosis. In 
those without predicted fibrosis, chronic HCV was not significantly associated with T2MI 
after accounting for potential confounders. Those with predicted severe fibrosis were 
uncommon in this cohort, and there were few MI events in that subgroup. Although we 
have presented the estimated relative hazard of MI outcomes among those with severe 
fibrosis, we are limited in our ability to discern whether risk of T2MI associated with HCV is 
greater in this subgroup as small sample size may have introduced instability into the relative 
risk estimates. In addition to overall replication of our findings, an ideal future study in this 
area would more comprehensively investigate the role of liver fibrosis in the relation of HCV 
with cardiovascular disease outcomes, particularly in those with advanced fibrosis. Bacterial 
infections and sepsis are known complications and major sources of morbidity for patients 
with cirrhosis (49). 
Strengths of this study include adjudicated ascertainment of MI events including typing, 
extensive follow-up of participants providing a wide range of information about potential 
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confounders, and the CNICS PRO assessment with the use of multiple imputation 
methodology that permitted inclusion of self-reported substance use in our analytic models. 
HCV infection status in most studies of HCV and MI was defined on the basis of either 
seropositivity for anti-HCV antibodies or administrative diagnosis codes for HCV (30-33, 
44, 45). These measures are likely to be less specific for chronic HCV infection compared to 
ascertainment on the basis of an RNA test as we did here. One study of the general 
population in an Arkansas medical system found that participants with detectable HCV 
RNA had a greater incidence of coronary heart disease than those who tested positive for 
antibodies against HCV but without detectable HCV RNA. In combination with the 
findings presented here, this supports the use of HCV RNA testing to identify chronic HCV, 
something that should be highly feasible with the increasing uptake of nucleic acid based 
tests for HCV in clinical practice (50).   
We were unable to differentiate whether HCV is associated with the incidence of 
sepsis itself, or T2MI as a complication of sepsis. This is an important area for future work. 
Because adjudication of causes of T2MI events must necessarily rely on expert judgement, 
some measurement error may have occurred when categorizing these complex medical 
events. Our study was also not sufficiently powered to assess causes of T2MI other than 
sepsis and stimulant-induced vasospasm. We also used HCV RNA testing performed in the 
course of routine clinical care, and therefore potentially missed some cases of chronic HCV 
in those who did not undergo RNA testing in that setting. Finally, because any study seeking 
to characterize the effects of HCV infection must be observational, the possibility of 
unmeasured and residual confounding cannot be completely excluded. In particular, we note 
that 87% of participants were lacking baseline information for self-reported substance use 
and time-varying substance use was not included in this analysis, leaving open the possibility 
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of confounding by differences in substance use in those with and without chronic HCV. 
However, this rich database of clinical and patient-reported information, combined with 
analytic techniques accommodating missingness in covariates, enabled us to adjust for many 
important potential confounders. 
In this large and diverse multicenter cohort of PLWH in the US, we found that 
chronic HCV infection at the beginning of follow-up was not associated with incident 
classical atheroembolic T1MI but was associated with T2MI attributed to sepsis. These 
findings demonstrate the importance of examining MIs by type among PLWH and support 
increasing calls for broad-scale efforts to better understand the biological underpinnings of 
T2MI, and ultimately identify effective management approaches (51). Further research is 
needed to replicate these findings, elucidate biological mechanisms and determine whether 
risk of sepsis and/or T2MI might be an important consideration for HCV treatment 
decisions in this high-burden population. 
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Table 1. Baseline Clinical and Demographic Characteristics of Adults Living With HIV in Clinical Care at 6 
CNICS Sites Across the U.S. in 1998-2016 by Chronic Hepatitis C Virus Infection Status 
Characteristic 
Chronic  
Hepatitis C  
No chronic 
Hepatitis C Everyone 
n 2280 21127 23407 
Demographic factors    
Male (%) 1779 (78.0)  17117 (81.0)  18896 (80.7)  
Age, years (%)              
   <30 108 (4.7)  3666 (17.4)  3774 (16.1)  
   30-39 511 (22.4)  6626 (31.4)  7137 (30.5)  
   40-49 931 (40.8)  7072 (33.5)  8003 (34.2)  
   50-59 619 (27.1)  3062 (14.5)  3681 (15.7)  
   ≥60 111 (4.9)  701 (3.3)  812 (3.5)  
Race & ethnicity (%)              
   Non-Hispanic, white 981 (43.0)  9096 (43.1)  10077 (43.1)  
   Non-Hispanic, black 984 (43.2)  8390 (39.7)  9374 (40.0)  
   Non-Hispanic, all other races 119 (5.2)  1036 (4.9)  1155 (4.9)  
   Hispanic, all races 196 (8.6)  2605 (12.3)  2801 (12.0)  
Men who have sex with men (%) 877 (39.0)  12897 (62.2)  13774 (59.9)  
Clinical Characteristics    
Hepatitis B virus (%) 101 (4.4) 1030 (4.9)  1131 (4.8)  
Diabetes (%) 163 (7.1)  1030 (4.9)  1193 (5.1)  
Hypertension (%) 350 (15.4)  2394 (11.3)  2744 (11.7)  
Statin use (%) 97 (4.3)  1422 (6.7)  1519 (6.5)  
Body mass index
a
 (mean (SD)) 25.6 (4.8) 25.9 (5.5) 25.9 (5.4) 
Total cholesterol
a
 (mean (SD)) 159.5 (41.0) 174.9 (45.5) 173.4 (45.3) 
HDL cholesterol (mean (SD)) 43.5 (17.2) 42.1 (15.2) 42.2 (15.4) 
Triglycerides
a
 (mean (SD)) 157.2 (124.1) 170.2 (154.0) 168.9 (151.4) 
FIB-4 score (%)              
   <1.45 1113 (49.5)  16420 (80.5)  17533 (77.5)  
   1.45-3.25 765 (34.0)  3314 (16.3)  4079 (18.0)  
   >3.25 370 (16.5)  654 (3.2)  1024 (4.5) 
HIV-related factors    
Nadir CD4+ cell count (%)              
   <100 556 (24.4)  5330 (25.2)  5886 (25.1)  
   100-199 421 (18.5)  2972 (14.1)  3393 (14.5)  
   200-349 559 (24.5)  4956 (23.5)  5515 (23.6)  
   350-499 389 (17.1)  3732 (17.7)  4121 (17.6)  
   ≥500 355 (15.6)  4137 (19.6)  4492 (19.2)  
CD4+ cell count (mean (SD)) 416.2 (273.9) 439.1 (285.1) 436.8 (284.1) 
CD8+ cell count
a
 (mean (SD)) 907.8 (503.9) 925.5 (508.8) 923.8 (508.3) 
Ratio of CD4+/CD8+ cells
a
 (%)    
   <0.4 716 (44.5)  6396 (41.7)  7112 (42.0)  
   0.4–1.0 699 (43.4)  6914 (45.1)  7613 (44.9)  
   >1.0 194 (12.1)  2031 (13.2)  2225 (13.1)  
HIV viral load ≤ 400 copies/mL (%) 1321 (58.1) 12607 (60.4) 13928 (60.2) 
Receiving ART at start of follow-up (%) 1911 (83.8)  17954 (85.0) 19865 (84.9) 
ART, antiretroviral therapy; FIB-4, Fibrosis-4 score; HIV, human immunodeficiency virus; SD, standard deviation 
a 
Values of this variable were unknown for greater than 5% of participants using information from the 6 months before 
initiation of myocardial infarction (MI) study follow-up. Percentages are of non-missing values. 
b 
Self-reported substance use was collected in a subset of participants because sites added the CNICS clinical assessment 
starting in 2006 with an additional site starting it every year or two until all CNICS sites included it. Percentages are of the 
subset of participants from all sites responding to the instrument in the CNICS clinical assessment addressing that domain 
prior to or at the start of follow-up. Approximately 13% of participants provided information about methamphetamine, 
cocaine, opiate, marijuana, cigarette and alcohol use. 
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c 
Measure of alcohol use based on the AUDIT-C questionnaire (41). Values range from 0 (least use) to 12 (most use). 
 
Table 1 (continued). Baseline Clinical and Demographic Characteristics of Adults Living With HIV in Clinical 
Care at 6 CNICS Sites, by Chronic Hepatitis C Virus Infection Status, 1998-2016 
Characteristic 
Chronic 
Hepatitis C  
No chronic 
Hepatitis C Everyone 
Substance use    
Ever smoker (%) 873 (38.3)  5160 (24.4)  6033 (25.8) 
History of injecting drug use (%) 1384 (61.5)  
 
3103 (15.0)  
 
4487 (19.5) 
Methamphetamine use
b
 (%)              
   Current 34 (15.9)  262 (9.0)  296 (9.5)  
   Former 77 (36.0)  704 (24.2)  781 (25.0)  
   Never 103 (48.1)  1944 (66.8)  2047 (65.5)  
Cocaine/crack use
b
 (%)               
   Current 31 (14.2)  181 (6.2)  212 (6.8) 
   Former 126 (57.8)  1040 (35.7)  1166 (37.2)  
   Never 61 (28.0)  1695 (58.1)  1756 (56.0)  
Illicit opiate use
b
 (%)               
   Current 18 (9.0)  67 (2.4)  85 (2.8) 
   Former 61 (30.5)  288 (10.2)  349 (11.5)  
   Never 121 (60.5)  2479 (87.5)  2600 (85.7)  
Marijuana use
b
 (%)               
   Current 64 (30.9)  887 (30.9)  951 (30.9)  
   Former 78 (37.7)  1014 (35.3)  1092 (35.5)  
   Never 65 (31.4)  969 (33.8)  1034 (33.6)  
Cigarette use
b
 (%)               
   Current 132 (57.4)  1100 (37.3)  1232 (38.7)  
   Former 52 (22.6)  642 (21.7)  694 (21.8)  
   Never 46 (20.0)  1210 (41.0)  1256 (39.5)  
AUDIT-C score
bc
 (mean (SD)) 1.84 (2.64) 2.36 (2.54) 2.33 (2.55) 
ART, antiretroviral therapy; FIB-4, Fibrosis-4 score; HIV, human immunodeficiency virus; SD, standard deviation 
a 
Values of this variable were unknown for greater than 5% of participants using information from the 6 months before 
initiation of myocardial infarction (MI) study follow-up. Percentages are of non-missing values. 
b 
Self-reported substance use was collected in a subset of participants because sites added the CNICS clinical assessment 
starting in 2006 with an additional site starting it every year or two until all CNICS sites included it. Percentages are of the 
subset of participants from all sites responding to the instrument in the CNICS clinical assessment addressing that domain 
prior to or at the start of follow-up. Approximately 13% of participants provided information about methamphetamine, 
cocaine, opiate, marijuana, cigarette and alcohol use. 
c 
Measure of alcohol use based on the AUDIT-C questionnaire (41). Values range from 0 (least use) to 12 (most use). 
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Table 2. Number of Type 2 Myocardial Infarctions (T2MI) Attributed to Causes Among Adults 
Living With HIV in Clinical Care at 6 CNICS Sites, 1998-2016 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Attributed cause Number of events (%) 
Sepsis/bacteremia 118 (35.8) 
Stimulant-induced vasospasm   37 (11.2) 
Hypertensive urgency/emergency   35 (10.6) 
Hypoxia   24   (7.3) 
Hypotension   20   (6.1) 
Arrhythmia   17   (5.2) 
Procedure related   14   (4.2) 
Gastrointestinal bleed   11   (3.3) 
Other rare causes   54 (16.4) 
Total 330 (100.0) 
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Figure 1. Forest plot of hazard ratios estimating the association of chronic hepatitis C virus infection with myocardial infarction outcomes 
among people living with HIV at 6 CNICS sites across the US. Fully adjusted models took into account age, sex at birth, race, ethnicity, site, 
men who have sex with men, ever smoker, history of injecting drug use, diabetes, statin use, hypertension, Hepatitis B virus, ART use, nadir 
CD4+ cell count, HIV viral load, body mass index, total cholesterol, HDL cholesterol, triglycerides, alcohol use score, and self-reported use of 
amphetamines, cocaine, opiates, marijuana, and cigarettes. 
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Figure 2. Forest plot of hazard ratios estimating the association of chronic hepatitis C virus infection with myocardial infarction outcomes 
among people living with HIV at 6 CNICS sites across the US in (A) the subset of participants with no predicted severe liver fibrosis (FIB-4 
score < 1.45) and (B) the subset with predicted severe liver fibrosis (FIB-4 score > 3.25). Fully adjusted models took into account age, sex at 
birth, race, ethnicity, site, men who have sex with men, ever smoker, history of injecting drug use, diabetes, statin use, hypertension, Hepatitis B 
virus, ART use, nadir CD4+ cell count, HIV viral load, body mass index, total cholesterol, HDL cholesterol, triglycerides, alcohol use score, and 
self-reported use of amphetamines, cocaine, opiates, marijuana, and cigarettes.
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  Number 
of events 
  aHR (95% CI) 
MI, all  666 1.28 (0.96-1.70) 
     
T1MI  336 1.19 (0.76-1.87) 
T2MI  330 1.23 (0.84-1.81) 
     
T2MI attributed to sepsis  37 1.21 (0.61-2.41) 
T2MI attributed to stimulant  118 1.68 (0.21-13.68) 
T2MI attributed to other causes  175 1.11 (0.64-1.90) 
 
Supplementary Figure 1. Forest plot of adjusted hazard ratios for incident MI outcomes in those with prior HCV 
infection without chronic infection compared to those without evidence of prior HCV infection (antibody negative). Prior 
HCV infection without active infection at the beginning of MI follow-up was defined as a positive result on the most 
recent HCV antibody test combined with a negative result on the most recent HCV RNA test. Hazard ratios are from 
Cox proportional hazard regression models adjusted for age, sex at birth, race, ethnicity, site, men who have sex with 
men, ever smoker, history of injecting drug use, diabetes, statin use, hypertension, Hepatitis B virus, ART use, lowest 
CD4+ cell count, HIV viral load, body mass index, total cholesterol, HDL cholesterol, triglycerides, alcohol use score 
and self-reported use of amphetamines, cocaine, opiates, marijuana, and cigarettes. Multiple imputation was used and 
parameters were pooled using Rubin’s rules. Abbreviations: aHR, adjusted hazard ratio; CI, confidence interval; MI, 
myocardial infarction; T1MI, Type 1 MI; T2MI, Type 2 MI 
 
 
Supplementary Table 1. Hazard ratios describing the association of chronic HCV with T2MI 
attributed to stimulant use 
Adjustment variables Hazard ratio 95% Confidence 
interval 
None (crude estimate) 2.60 1.19, 5.70 
Age, sex 2.20 1.00, 4.85 
Age, sex, history of injecting drug use 1.18 0.51, 2.75 
All covariates without substance use PROs 1.07 0.45, 2.55 
All covariates with substance use PROs 0.96 0.15, 6.14 
Hazard ratios are from Cox proportional hazards regression models estimating incident myocardial 
infarction outcomes in those with chronic HVC infection compared to those without evidence of chronic 
HCV infection. Covariates were age, sex at birth, race, ethnicity, site, men who have sex with men, ever 
smoker, history of injecting drug use, diabetes, age, sex at birth, race, ethnicity, site, men who have sex 
with men, ever smoker, history of injecting drug use, diabetes, statin use, hypertension, Hepatitis B virus, 
ART use, lowest CD4+ cell count, HIV viral load, body mass index, total cholesterol, HDL cholesterol, 
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triglycerides, alcohol use score and self-reported use of amphetamines, cocaine, opiates, marijuana, and 
cigarettes. Multiple imputation was used and parameters were pooled using Rubin’s rules. Boldface 
indicates significance at α=0.05.  
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